Поражения органов пищеварения при COVID-19: современное состояние проблемы


DOI: https://dx.doi.org/10.18565/therapy.2021.4.72-80

А.М. Осадчук, И.Д. Лоранская, М.А. Осадчук, Е.В. Степанова, А.И. Парусов

1) ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, г. Москва; 2) ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)
Аннотация. По опубликованным данным, распространенность желудочно-кишечных симптомов при тяжелом течении COVID-19 может достигать 50%. Кроме прямого вирусного воздействия, органы пищеварительного тракта могут подвергаться лекарственному поражению на фоне системных циркуляторных расстройств, ассоциированных с SARS-CoV-2. При этом диагностика поражений органов пищеварения может серьезно запаздывать из-за доминирования более серьезных респираторных симптомов COVID-19, что в значительной мере ухудшает течение и прогноз основного заболевания. Представленные в обзоре сведения по эпидемиологии, этиопатогенезу, диагностике и лечению поражений органов пищеварительного тракта у пациентов с COVID-19 значительно расширяют знания врачей о внелегочных проявлениях инфекции, что дает возможность оптимизировать тактику ведения и уменьшить риск развития неблагоприятных исходов.
Ключевые слова: эпидемиология клинических проявлений, SARS-CoV-2, COVID-19, колит, панкреатит, гепатит, гастрит
Полный текст статьи доступен
в "Библиотеке Врача"

Литература


  1. Fontanesi L., Marchetti D., Mazza C. et al. The effect of the COVID-19 lockdown on parents: A call to adopt urgent measures. Psychol Trauma. 2020; 12(S1): S79–S81. doi: 10.1037/tra0000672.

  2. Mazza C., Ricci E., Marchetti D. et al. How personality relates to distress in parents during the Covid-19 lockdown: The mediating role of child’s emotional and behavioral difficulties and the moderating effect of living with other people. Int J Environ Res Public Health. 2020; 17(17): 6236. doi: 10.3390/ijerph17176236.

  3. Di Crosta A., Palumbo R., Marchetti D. et al. Individual differences, economic stability, and fear of contagion as risk factors for PTSD symptoms in the COVID-19 emergency. Front Psychol. 2020; 11: 567367. doi: 10.3389/fpsyg.2020.567367.

  4. Зольникова О.Ю., Джахая Н.Л., Поцхверашвили Н.Д. с соавт. Клинические особенности пациентов с SARS-CoV-2-инфекцией. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020; 6: 28–39.

  5. Walker M. Chronic liver conditions raise risk of death in COVID-19 patients. MedPage Today. November 16, 2020. URL: https://www.medpagetoday.com/meetingcoverage/aasld/89710 (date of access – 02.04.2020).

  6. Jin X., Lian J.S., Hu J.H. et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020; 69(6): 1002–09. doi: 10.1136/gutjnl-2020-320926.

  7. Pan L., Mu M., Yang P. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive cross-sectional multicenter study. Am J Gastroenterol. 2020; 115(5): 766–73. doi: 10.14309/ajg.0000000000000620.

  8. Cheung K.S., Ivan F.N., Hung M.D. et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology. 2020; 159(1): 81–95. doi: 10.1053/j.gastro.2020.03.065.

  9. D’Amico F., Baumgart D.C., Danese S., Peyrin-Biroulet L. Diarrhea during COVID-19 infection: Pathogenesis, epidemiology, prevention, and management. Clin Gastroenterol Hepatol. 2020; 18(8): 1663–72. doi: 10.1016/j.cgh.2020.04.001.

  10. Docherty A.B., Harrison E.M., Green C.A. et al. ISARIC4C investigators. Features of 20,133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020; 369: m1985. doi: 10.1136/bmj.m1985.

  11. Argenziano M.G., Bruce S.L., Slater C.L. et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020; 369: m1996. doi: 10.1136/bmj.m1996.

  12. Arjmand B., Ghorbani F., Koushki M. et al. Gastrointestinal symptoms in patients with mild and severe COVID-19: a scoping review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2020; 13(4): 321–30.

  13. Andrews P.L.R., Cai W., Rudd J.A., Sanger G.J. COVID-19, nausea, and vomiting. J Gastroenterol Hepatol. 2021; 36(3): 646–56. doi: 10.1111/jgh.15261.

  14. Al-Ani R.M., Acharya D. Prevalence of anosmia and ageusiain patients with COVID-19 at primary Health Center, Doha, Qatar. Indian J Otolaryngol Head Neck Surg. 2020: 1–7. doi: 10.1007/s12070-020-02064-9.

  15. Hunt R.H., East J.E., Lanas A. et al. COVID-19 and gastrointestinal disease: Implications for the gastroenterologist. Dig Dis. 2021; 39(2): 119–39. doi: 10.1159/000512152.

  16. Rokkas T. Gastrointestinal involvement in COVID-19: a systematic review and meta-analysis. Ann Gastroenterol. 2020; 33(4): 355–65. doi: 10.20524/aog.2020.0506.

  17. Han C., Duan C., Zhang S. et al. Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol. 2020; 115(6): 916–23. doi: 10.14309/ajg.0000000000000664.

  18. Parasa S., Desai M., Chandrasekar V.T. et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: A systematic review and meta-analysis. JAMA Netw Open. 2020; 3(6): e2011335. doi: 10.1001/jamanetworkopen.2020.11335.

  19. Garrido I., Liberal R., Macedo G. COVID-19 and liver disease-what we know on 1st May 2020. Aliment Pharmacol Ther. 2020; 52(2): 267–75. doi:10.1111/apt.15813.

  20. Cai Q., Huang D., Yu H.et al. COVID-19: Abnormal liver function tests. J Hepatol. 2020; 73: 566–74. doi: 10.1016/j.jhep.2020.04.006.

  21. Gadour E., Hassan Z., Shrwani K. Covid-19 induced hepatitis (CIH), definition and diagnostic criteria of a poorly understood new clinical syndrome. Gut 2020; 69 (Suppl 1): A1–A51. doi: 10.47690/WJGHE.2020.3301.

  22. Wang Y., Liu S., Liu H. et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020; 73: 807–16 .doi: 10.1016/j.jhep.2020.05.002.

  23. Boettler T., Marjot T., Newsome P.N. et al. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep. 2020; 2(5): 100169. doi: 10.1016/j.jhepr.2020.100169.

  24. Vespa E., Pugliese N., Piovani D. et al. Liver tests abnormalities in COVID-19: trick or treat?. J Hepatol. 2020; 73(5): 1275–76. doi: 10.1016/j.jhep.2020.05.033.

  25. Kumar A., Kumar P., Dungdung A. et al. Pattern of liver function and clinical profile in COVID-19: A cross-sectional study of 91 patients. Diabetes Metab Syndr. 2020; 14(6): 1951–54. doi: 10.1016/j.dsx.2020.10.001.

  26. Zuo T., Liu Q., Zhang F. et al. Depicting SARSCoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021; 70: 276–84. doi: 10.1136/gutjnl-2020-322294.

  27. 2Massironi S., Vigano C., Dioscoridi L. et al. Endoscopic findings in patients infected with 2019 novel coronavirus in Lombardy, Italy. Clin Gastroenterol Hepatol. 2020; 18(10): 2375–77. doi: 10.1016/j.cgh.2020.05.045.

  28. Inamdar S., Benias P.C., Liu Y. et al. Prevalence, risk factors, and outcomes of hospitalized patients with COVID-19 presenting as acute pancreatitis. Gastroenterology. 2020; 159(6): 2226–28.e2. doi: 10.1053/j.gastro.2020.08.044.

  29. Wang F., Wang H., Fan J. et al. Pancreatic injury patterns in patients with coronavirus disease 19 pneumonia. Gastroenterology. 2020; 159(1): 367–70. doi: 10.1053/j.gastro.2020.03.055.

  30. Tositti G., Fabris P., Barnes E.et al. Pancreatic hyperamylasemia during acute gastroenteritis: incidence and clinical relevance. BMC Infect Dis. 2001; 1(1): 18. doi: 10.1186/1471-2334-1-18.

  31. Dirweesh A., Li Y., Trikudanathan G. et al. Clinical outcomes of acute pancreatitis in patients with coronavirus disease 2019. Gastroenterology 2020; 159: 1972–74. doi: 10.1053/j.gastro.2020.07.038.

  32. Balaphas A., Gkoufa K., Meyer J. et al. Covid-19 can mimic acute cholecystitis and is associated with the presence of viral RNA in the gallbladder wall. J Hepatol. 2020; 73(6): 1566–68. doi: 10.1016/j.jhep.2020.08.020.

  33. Xiao F., Tang M., Zheng X. et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020; 158(6): 1831–33.e3. doi: 10.1053/j.gastro.2020.02.055.

  34. Connors J.M., Levy J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020; 135(23): 2033–40. doi: 10.1182/blood.2020006000.

  35. Lanas A., Dumonceau J.M., Hunt R.H. et al. Non-variceal upper gastrointestinal bleeding. Nat Rev Dis Primers. 2018; 4: 18020. doi: 10.1038/nrdp.2018.20.

  36. Zuo T., Zhang F., Lui G.C.Y. et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020; 159(3): 944–55.e8. doi: 10.1053/j.gastro.2020.05.048.

  37. Pan Y., Zhang D., Yang P. et al. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020; 20(4): 411–12. doi: 10.1016/S1473-3099 (20) 30113-4.

  38. Huizen J. (Fact checked by Alexandra Sanfins, Ph.D.) Gastrointestinal symptoms in COVID-19: What we know so far and why it is important. Medical News Today. 12 February 2021. URL: https://www.medicalnewstoday.com/articles/gastrointestinal-symptoms-in-covid-19-what-do-we-know-so-far (date of access – 02.04.2021).

  39. Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARSCoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5): 475–81. doi: 10.1016/S2213-2600(20)30079-5.

  40. Chan K.H., Lim S.L., Damati A. et al. Coronavirus disease 2019 (COVID-19) and ischemic colitis: An under-recognized complication. Am J Emerg Med. 2020; 38(12): 2758.e1–2758.e4. doi: 10.1016/j.ajem.2020.05.072.

  41. Levi M., Thachil J., Iba T., Levy J.H. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020; 7(6): e438–40. doi: 10.1016/S2352-3026(20)30145-9.

  42. Farina D., Rondi P., Botturi E. et al. Gastrointestinal: bowel ischemia in a suspected coronavirus disease (COVID-19) patient. J J Gastroenterol Hepatol. 2021; 36(1): 41. doi: 10.1111/jgh.15094.

  43. Tian Y., Rong L., Nian W. Gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020; 51: 843–51.

  44. Muus C., Luecken M.D., Eraslan G. et al. Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARS-CoV-2 viral entry and highlights inflammatory programs in putative target cells. bioRxiv. 2020: 2020.04.19.049254. doi: 10.1101/2020.04.19.049254.

  45. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2): 271–80.e8. doi: 10.1016/j.cell.2020.02.052.

  46. Yang L., Han Y., Nilsson-Payant B.E. et al. A human pluripotent stem cell-based platform to study SARSCoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020; 27(1): 125–136.e7. doi: 10.1016/j.stem.2020.06.015.

  47. Iavarone M., D’Ambrosio R., Soria A. et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020; 73(5): 1063–71. doi: 10.1016/j.jhep.2020.06.001.

  48. Puelles V.G., Lutgehetmann M., Lindenmeyer M.T. et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020; 383(6): 590–92. doi: 10.1056/NEJMc2011400.

  49. Wichmann D., Sperhake J.P., Lutgehetmann M. et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020; 173(4): 268–77. doi: 10.7326/M20-2003.

  50. Tian S., Xiong Y., Liu H. et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020; 33(6): 1007–14. doi: 10.1038/s41379-020-0536-x.

  51. Bangash M.N., Patel J.M., Parekh D. et al. SARSCoV-2: is the liver merely a bystander to severe disease? J Hepatol. 2020; 73(4): 995–96. doi: 10.1016/j.jhep.2020.05.035.

  52. Chai X., Hu L., Zhang Y. et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020.02.03.931766. doi: 10.1101/2020.02.03.931766.

  53. Zhang C., Shi L., Wang F.S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5): 428–30. doi: 10.1016/S2468-1253(20)30057-1.

  54. Anand S., Mande S.S. Diet, microbiota and gut-lung connection. Front Microbiol. 2018; 9: 2147. doi: 10.3389/fmicb.2018.02147.

  55. Groves H.T., Higham S.L., Moffatt M.F. et al. Respiratory viral infection alters the gut microbiota by inducing inappetence. MBio. 2020; 11(1): e03236–19. doi: 10.1128/mBio.03236-19.

  56. Gu S., Chen Y., Wu Z. et al. Alterations of the gut microbiota in patients with COVID-19 or H1N1 influenza. Clin Infect Dis. 2020; 71(10): 2669–78. doi: 10.1093/cid/ciaa709.

  57. Hu Y., Lu G.-Z., Xu J. Discussion on symptoms of digestive tract caused by novel coronavirus infection. Chinese J Infect Dis 38: 2020. doi: 10.3760/cma.j.cn311365-20200220-00094.

  58. Zeng J., Wang C.T., Zhang F.S. et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med. 2016; 42(6): 1018–28. doi: 10.1007/s00134-016-4303-x.

  59. Brenner E.J., Ungaro R.C., Colombel J.F. et al. SECURE-IBD data base public data update

  60. van Paassen J., Vos J.S., Hoekstra E.M. et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020; 24(1): 696. doi: 10.1186/s13054-020-03400-9.

  61. Brain O., Satsangi J. Therapeutic decisions in inflammatory bowel disease in the SARS-CoV-2 pandemic. 2020; 15: S0016-5085(20)34775-2. doi: 10.1053/j.gastro.2020.05.083.

  62. Cai Q., Huang D., Yu H. et al. COVID-19: Abnormal liver function tests. Journal of Hepatology. 2020; 73: 566–74. doi: 10.1016/j.jhep.2020.04.006.

  63. Lerch M.M., Saluja A.K., Dawra R. et al. The effect of chloroquine dministration on two experimental models of acute pancreatitis. Gastroenterology. 1993; 104(6): 1768–79. doi: 10.1016/0016-5085(93)91022-a.

  64. Frommeyer G., Fischer C., Ellermann C. et al. Severe proarrhythmic potential of the antiemetic agents ondansetron and domperidone. Cardiovasc Toxicol. 2017; 17(4): 451–57. doi: 10.1007/s12012-017-9403-5.

  65. Lee S.W., Ha E.K., Yeniova A.O. et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021; 70(1):76–84. doi: 10.1136/gutjnl-2020-322248.


Об авторах / Для корреспонденции

Алексей Михайлович Осадчук, д.м.н., профессор, профессор кафедры гастроэнтерологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. Адрес: 123242,
г. Москва, ул. Баррикадная, д. 2/1, стр. 1. Тел.: 8 (927) 606-09-40. E-mail: a.m.osadchuk2020@mail.ru. eLibrary SPIN: 9455-3982, ID 651113. ORCID: 0000-0002-8488-9235. Web of Science: Р – 9213-2015. Scopus ID: 24576966600
Ирина Дмитриевна Лоранская, д.м.н., профессор, зав. кафедрой гастроэнтерологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. Адрес: 123242, г. Москва, ул. Баррикадная, д. 2/1, стр. 1. Тел.: 8 (903) 188-64-78. E-mail: gastromapo@yandex.ru. eLibrary SPIN: 1793-1080, ID: 370313. ORCID: 0000-0002-3681-4132. Scopus ID: 36164230100.
Михаил Алексеевич Осадчук, д.м.н., профессор, зав. кафедрой поликлинической терапии ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет). Адрес: 119435, г. Москва, ул. Большая Пироговская, д. 2/9. Тел.: 8 (916) 071-26-26. E-mail: osadchuk.mikhail@yandex.ru. eLibrary SPIN: 3108-0478. ORCID: 0000-0003-0485-6802. Web of Science; В-9896-2018. Scopus ID: 6701741609
Елена Владимировна Степанова, к.м.н., доцент, доцент кафедры гастроэнтерологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. Адрес: 123242,
г. Москва, ул. Баррикадная, д. 2/1, стр. 1. Тел.: 8 (916) 590-35-00. E-mail: gmunden2011@yandex.ru. ORCID: 0000-0002-0657-1280
Андрей Игоревич Парусов, ассистент кафедры гастроэнтерологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. Адрес: 123242, г. Москва, ул. Баррикадная, д. 2/1, стр. 1. Тел.: 8 (919) 005-27-71. E-mail: andre_webster@mail.ru. eLibrary SPIN: 2181-9058. ORCID: 0000-0002-2379-0960


Похожие статьи

К содержанию номера

Бионика Медиа